Dopamine precursor with peripheral decarboxylase inhibitor

This page covers all Dopamine precursor with peripheral decarboxylase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition), Aromatic amino acid decarboxylase (AADC); dopamine pathway, Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine).

Targets

Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition) · Aromatic amino acid decarboxylase (AADC); dopamine pathway · Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine) · Aromatic L-amino acid decarboxylase (AADC); dopaminergic system · Aromatic amino acid decarboxylase (AADC); dopaminergic system · Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa) · Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide) · Aromatic amino acid decarboxylase (peripheral inhibition); dopamine receptors (central effect) · Aromatic L-amino acid decarboxylase (carbidopa); dopamine pathway (levodopa) · Dopamine pathway; aromatic L-amino acid decarboxylase (carbidopa component)

Marketed (9)

• Levodopa + benserazide · University of Buenos Aires · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter in Parkinson's disease, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.
• Levodopa / Carbidopa · Ross D. Zafonte, MD · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.
• Levodopa Benserazide Teva Italia · IRCCS San Raffaele Roma · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.
• controlled-release levodopa / carbidopa · Pfizer · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits its premature breakdown in the periphery, allowing more levodopa to reach the brain.
• Sinemet (comparator) · XenoPort, Inc. · Neurology
  Sinemet combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) to increase dopamine levels in the brain while preventing peripheral conversion of levodopa.
• L-DOPA/DDCI · Bial - Portela C S.A. · Neurology
  L-DOPA is converted to dopamine in the brain to replace deficient neurotransmitter levels, while DDCI (a decarboxylase inhibitor) prevents premature conversion of L-DOPA in the periphery, allowing more to reach the central nervous system.
• Levodopa and carbidopa · NeuroDerm Ltd. · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion of levodopa in the periphery, allowing more to reach the brain.
• Levodopa Benserazide Madopar · IRCCS San Raffaele Roma · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while benserazide inhibits peripheral conversion of levodopa to prevent side effects.
• levodopa/dopa decarboxylase inhibitor · Bial - Portela C S.A. · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while the dopa decarboxylase inhibitor prevents premature conversion in the periphery, allowing more levodopa to reach the brain.

Phase 3 pipeline (2)

• Accordion Pill™ Carbidopa/Levodopa · Intec Pharma Ltd. · Neurology
  The Accordion Pill™ is a modified-release formulation that delivers carbidopa and levodopa sequentially to optimize absorption and reduce motor fluctuations in Parkinson's disease.
• Levodopa/Carbidopa (LD/CD) · AbbVie · Neurology
  Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion in the periphery, allowing more levodopa to reach the central nervous system.

Patent intelligence

• dopamine precursor with peripheral decarboxylase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates